Moderna Shares Slip After Analyst Day Reveals Rising Medium-Term Cash Costs

Moderna stock dropped more than 6% in early trading before clawing back to a 2% loss by late morning on Thursday. The volatility followed a company analyst day where executives detailed financial guidance through the end of the decade, leaving investors weighing upbeat near-term margin improvements against looming multi-billion dollar cash expenditures.

For the year 2026, management projected revenue growth between 15% and 25%, surpassing earlier forecasts of 10% growth and pointing toward roughly $2.3 billion in revenue. While this figure trails the $2.4 billion consensus estimate tracked by Yahoo! Finance, the company also anticipates firmer profit margins and accelerated cost savings that could help reduce per-share losses compared to the expected $7.37 per share projected for 2025.

However, market enthusiasm was tempered by Moderna's outlook for 2027 and beyond. The firm moved up its cash cost framework, signaling approximately $4 billion in cash costs for 2027—matching the burn rate seen in 2023 and 2024 and doubling the $2.1 billion expected for 2025. Furthermore, management indicated that annual cash costs will average between $4 billion and $4.5 billion from 2027 through 2030, raising fresh questions about medium-term capital efficiency.

What to watch next: Investors will be tracking actual progress on margin improvements through upcoming quarterly earnings reports to see if cost-containment measures can offset the anticipated rise in medium-term cash burn.